Differential seroreactivity of p53 and p63 proteoforms showed individual areas under the curve (AUCs) to discriminate the pathological group (CRC patients and premalignant individuals) from healthy individuals up to 80.9% and 77.7%, with specificity up to 85.4% and 79.2%, and sensitivity up to 90.3% and 80.6%, respectively (Table S5 and Figure 5). Here, TP63 is linked to colorectal carcinoma.